$4.92 Billion is the total value of Avidity Partners Management LP's 98 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | SPDR SER TRcall | $321,404,000 | – | 4,052,000 | +100.0% | 6.53% | – | |
| PRTA | New | PROTHENA CORP PLC | $119,259,000 | – | 1,967,000 | +100.0% | 2.42% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $106,304,000 | – | 3,122,000 | +100.0% | 2.16% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $104,814,000 | – | 948,200 | +100.0% | 2.13% | – |
| AXSM | New | AXSOME THERAPEUTICS INC | $68,652,000 | – | 1,538,600 | +100.0% | 1.40% | – |
| BIO | New | BIO RAD LABS INCcl a | $60,402,000 | – | 144,800 | +100.0% | 1.23% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $57,746,000 | – | 288,500 | +100.0% | 1.17% | – |
| ZLAB | New | ZAI LAB LTDadr | $42,203,000 | – | 1,234,000 | +100.0% | 0.86% | – |
| PLRX | New | PLIANT THERAPEUTICS INC | $41,385,000 | – | 1,981,100 | +100.0% | 0.84% | – |
| DXCM | New | DEXCOM INC | $37,661,000 | – | 467,600 | +100.0% | 0.77% | – |
| SYK | New | STRYKER CORPORATION | $37,409,000 | – | 184,700 | +100.0% | 0.76% | – |
| VERV | New | VERVE THERAPEUTICS INC | $35,817,000 | – | 1,042,706 | +100.0% | 0.73% | – |
| CNC | New | CENTENE CORP DEL | $33,645,000 | – | 432,400 | +100.0% | 0.68% | – |
| NGM | New | NGM BIOPHARMACEUTICALS INC | $23,519,000 | – | 1,798,100 | +100.0% | 0.48% | – |
| PNT | New | POINT BIOPHARMA GLOBAL INC | $21,799,000 | – | 2,820,000 | +100.0% | 0.44% | – |
| COGT | New | COGENT BIOSCIENCES INC | $20,257,000 | – | 1,357,700 | +100.0% | 0.41% | – |
| BGNE | New | BEIGENE LTDsponsored adr | $17,796,000 | – | 132,000 | +100.0% | 0.36% | – |
| GOSS | New | GOSSAMER BIO INC | $17,371,000 | – | 1,450,000 | +100.0% | 0.35% | – |
| CYTK | New | CYTOKINETICS INC | $16,231,000 | – | 335,000 | +100.0% | 0.33% | – |
| ARQT | New | ARCUTIS BIOTHERAPEUTICS INC | $15,183,000 | – | 794,500 | +100.0% | 0.31% | – |
| PCVX | New | VAXCYTE INC | $15,089,000 | – | 628,700 | +100.0% | 0.31% | – |
| KNTE | New | KINNATE BIOPHARMA INC | $14,491,000 | – | 1,212,611 | +100.0% | 0.30% | – |
| TMDX | New | TRANSMEDICS GROUP INC | $12,522,000 | – | 300,000 | +100.0% | 0.26% | – |
| SGMO | New | SANGAMO THERAPEUTICS INC | $11,568,000 | – | 2,360,800 | +100.0% | 0.24% | – |
| STOK | New | STOKE THERAPEUTICS INC | $11,442,000 | – | 891,100 | +100.0% | 0.23% | – |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $8,916,000 | – | 698,200 | +100.0% | 0.18% | – |
| SGRY | New | SURGERY PARTNERS INC | $6,262,000 | – | 267,600 | +100.0% | 0.13% | – |
| New | SYROS PHARMACEUTICALS INC | $5,796,000 | – | 900,000 | +100.0% | 0.12% | – | |
| ACIU | New | AC IMMUNE SA | $869,000 | – | 274,876 | +100.0% | 0.02% | – |
| New | REUNION NEUROSCIENCE INC | $851,000 | – | 595,200 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.